PhotoImmune Biotechnology Inc., Houston, TX, United States; The McGovern University of Texas Medical School at Houston, United States.
Curr Opin Virol. 2018 Apr;29:26-32. doi: 10.1016/j.coviro.2018.02.004. Epub 2018 Mar 14.
There is consensus that only a preventive vaccine can contain the HIV/AIDS pandemic. After 30 years still there is no preventive HIV vaccine. This article examines fundamental challenges to the development of a preventive HIV vaccine. They include the initially erroneous but powerful perception of the natural history of HIV disease, as an acute rather than a chronic illness even in the absence of therapy, the lack of appreciation of the quasispecies biology of HIV and the abandonment of principles of immunology theory caused by the allure of technological prowess. In addition two other important aspects are discussed: vaccines directed against transmitted/founder viruses (T/F) and the reconsideration of HIV inactivation as a viable means to obtain a preventive HIV vaccine using novel safe methods of inactivation not available during the early years of the pandemic.
人们普遍认为,只有预防性疫苗才能控制艾滋病的流行。30 年过去了,仍然没有预防性艾滋病疫苗。本文探讨了开发预防性艾滋病疫苗所面临的一些基本挑战。其中包括对 HIV 疾病自然史的最初错误但强大的认识,即即使在没有治疗的情况下,它也是一种急性而不是慢性疾病;对 HIV 准种生物学缺乏认识;以及对免疫学理论原则的抛弃,这些都是因为技术实力的诱惑。此外,还讨论了另外两个重要方面:针对传播/原始病毒(T/F)的疫苗,以及重新考虑 HIV 失活作为一种可行手段,利用在大流行早期不可用的新型安全失活方法来获得预防性 HIV 疫苗。